Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma

    NEXT STORY
    Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
    PREV STORY
    Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients

    author_avatar
    NASDAQ Market News

    Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

    COPENHAGEN, Denmark, May 18, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced ...

    author_avatar
    NASDAQ Market News

    Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

    author_avatar
    NASDAQ Market News